BEMPEDOIC ACID 180 MG + EZETIMIBE 10 MG FIXED-DOSE COMBINATION VS EZETIMIBE ALONE OR PLACEBO IN PATIENTS WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA

Autor: Christie M. Ballantyne, Harold Bays, Eliot Brinton, Seth J. Baum, JoAnn Flaim, Jorge Plutzky, Zhan Ye

Publikováno v: Journal of the American College of Cardiology. 75:1983

Patients with type 2 diabetes mellitus (T2DM) are at high cardiovascular risk. National and international guidelines recommend aggressive low-density lipoprotein cholesterol (LDL-C) lowering with statin therapy; however, statins may increase glucose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15377c870d03fed13ee9eb382929cd00
https://doi.org/10.1016/s0735-1097(20)32610-3

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

Autor: JoAnn Flaim, Wai Chin, Shariq Ali, Michael H. Davidson, William C. Cromwell, Gregory S. Thomas

Publikováno v: Journal of the American College of Cardiology. 62(23):2178-2184

Objectives This study sought to examine the efficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in patients with hypercholesterolemia. Background Many patients on lipid-lowering therapies remain unable to achieve target

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cfe52b75d6662936a07109045833dbd

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

Autor: Diane Tribble, Mark K. Wedel, John J.P. Kastelein, Fatima Akdim, Brenda F. Baker, JoAnn Flaim, Rosie Z. Yu, Rainard Fuhr, Richard S. Geary, John Su

Publikováno v: European heart journal, 32(21), 2650-2659. Oxford University Press

Aims Mipomersen, an apolipoprotein (apo) B synthesis inhibitor, has been shown to produce potent reductions in apoB and LDL-cholesterol levels in animal models as well as healthy human volunteers. A randomized, double-blind, placebo-controlled, dose-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a30abfe1b416e8a71b67eaaa5206fe4b
https://doi.org/10.1093/eurheartj/ehr148

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

Autor: Mark K. Wedel, Mieke D. Trip, John Su, Erik S.G. Stroes, J. Wouter Jukema, Eric J.G. Sijbrands, Diane Tribble, Brenda F. Baker, John J.P. Kastelein, Rosie Z. Yu, JoAnn Flaim, Fatima Akdim

Publikováno v: Journal of the American College of Cardiology, 55(15), 1611-1618. Elsevier Inc.
Journal of the American College of Cardiology, 55(15), 1611-1618
Journal of the American College of Cardiology, 55(15), 1611-1618. Elsevier USA

Objectives The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy. Background Mipomersen is an apolipoprotein (apo) B synthesis inhibitor that has demonstrated signifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e754c064d779a828122d09d679769d0

Abstract 16993: An Antisense Inhibitor of Apolipoprotein C-III Significantly Decreases Nonesterified Fatty Acid Levels in Severe Hypertriglyceridemic Patients

Autor: Veronica Alexander, Diane Brisson, JoAnn Flaim, Steve Hughes, Walter Singleton, Richard Geary, Daniel Gaudet

Publikováno v: Circulation. 130

Background: Apolipoprotein C-III (apoC-III), a CV risk factor, plays a pivotal role in regulating plasma triglyceride (TG) levels. Elevated TG and its nonesterified fatty acid (NEFA) derivatives are associated with insulin resistance and type 2 diabe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37384d2d785e43c4eb101f3545d0e38e
https://doi.org/10.1161/circ.130.suppl_2.16993